NCT00943592

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

Clofarabine-melphalan-alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 82 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a clinical research study designed to evaluate whether a conditioning regimen consisting of the combination of three drugs named melphalan, alemtuzumab and clofarabine supported by donor blood cells will result in rapid recovery and a high rate of long-lasting remissions in patients with leukemia, lymphoma and myeloma.

Conditions

• Advanced Hematologic Malignancies
• Leukemia
• Preleukemia

Interventions

Type	Name	Description
DRUG	Clofarabine	Clofarabine will be administered as a 2-hour IV infusion on Days 1 through 5 at approximately the same time everyday (4 dose levels).
DRUG	Melphalan	Doses ranging from 100 to 140 mg/m2
DRUG	Campath	20mg/d x5
PROCEDURE	Stem Cell Transplant	Infusion of donor, bone marrow and auto.

Timeline

• Start date: 2006-03-01
• Primary completion: 2011-04-01
• Completion: 2013-11-01
• First posted: 2009-07-22
• Last updated: 2014-02-27
• Results posted: 2014-02-27

Locations

1 site across 1 country: United States